Immune Therapy for kidney cancer: A second dawn?

Seminars in Oncology

Volumn 40, Issue 4, 2013, Pages 492-498

  McDermott, David F ^a   Atkins, Michael B ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; CARBONATE DEHYDRATASE IX; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FRESOLIMUMAB; INTERFERON; INTERLEUKIN 2; INTERLEUKIN 21; IPILIMUMAB; NIVOLUMAB; PAZOPANIB; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TICILIMUMAB; TOLL LIKE RECEPTOR AGONIST; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; URELUMAB;

ANTIANGIOGENIC THERAPY; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER PATIENT; CANCER TEST; CANCER THERAPY; CLINICAL DECISION MAKING; CLINICAL PATHWAY; COHORT ANALYSIS; COLORECTAL CANCER; DENDRITIC CELL; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; FATIGUE; HEALTH CARE QUALITY; HEPATITIS; HUMAN; HYPOPHYSITIS; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; KIDNEY CARCINOMA; KIDNEY TUMOR; MAXIMUM TOLERATED DOSE; META ANALYSIS; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; NEPHRECTOMY; NEPHROTOXICITY; OVERALL SURVIVAL; PATIENT REFERRAL; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SUPPRESSOR CELL; TUMOR CELL; TUMOR IMMUNOLOGY; TUMOR REGRESSION;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; CYTOKINES; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84883144372     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.05.008     Document Type: Article

References (51)

1. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
2. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
3. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
4. B. Escudier, A. Pluzanska, and P. Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111
5. R.I. Fisher, S.A. Rosenberg, and G. Fyfe Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma Cancer J Sci Am 6 Suppl 1 2000 S55 S57
6. K.A. Margolin, A.A. Rayner, and M.J. Hawkins Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines J Clin Oncol 7 1989 486 498
7. G. Fyfe, R.I. Fisher, S.A. Rosenberg, M. Sznol, D.R. Parkinson, and A.C. Louie Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy J Clin Oncol 13 1995 688 696
8. A.J. Korman, K.S. Peggs, and J.P. Allison Checkpoint blockade in cancer immunotherapy Adv Immunol 90 2006 297 339
9. M.E. Keir, L.M. Francisco, and A.H. Sharpe PD-1 and its ligands in T-cell immunity Curr Opin Immunol 19 2007 309 314
10. Y. Iwai, M. Ishida, and Y. Tanaka Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade Proc Natl Acad Sci U S A 99 2002 12293 12297
11. H.B. Muss, J.J. Costanzi, and R. Leavitt Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration J Clin Oncol 5 1987 286 291
12. S. Negrier, A. Caty, and T. Lesimple Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Francais d'Immunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer J Clin Oncol 18 2000 4009 4015
13. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet. 1999;353:14-17
14. S. Pyrhonen, E. Salminen, and M. Ruutu Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer J Clin Oncol 17 1999 2859 2867
15. C. Coppin, F. Porzsolt, A. Awa, J. Kumpf, A. Coldman, and T. Wilt Immunotherapy for advanced renal cell cancer Cochrane Database Syst Rev 2005 CD001425
16. S. Negrier, B. Escudier, and C. Lasset Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie N Engl J Med 338 1998 1272 1278
17. J.C. Yang, R.M. Sherry, and S.M. Steinberg Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer J Clin Oncol 21 2003 3127 3132
18. D.F. McDermott, M.M. Regan, and J.I. Clark Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma J Clin Oncol 23 2005 133 141
19. S. Negrier, D. Perol, and A. Ravaud Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial Cancer 110 2007 2468 2477
20. T. Cangiano, J. Liao, J. Naitoh, F. Dorey, R. Figlin, and A. Belldegrun Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy J Clin Oncol 17 1999 523 528
21. R.J. Motzer, J. Bacik, T. Mariani, P. Russo, M. Mazumdar, and V. Reuter Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology J Clin Oncol 20 2002 2376 2381
22. M.P. Upton, R.A. Parker, A. Youmans, D.F. McDermott, and M.B. Atkins Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy J Immunother 28 2005 488 495
23. M.H. Bui, D. Seligson, and K.R. Han Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy Clin Cancer Res 9 2003 802 811
24. M. Atkins, M. Regan, and D. McDermott Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer Clin Cancer Res 11 2005 3714 3721
25. D. McDermott The high-dose Aldesleukin (HD IL-2) "SELECT" trial in patients with metastatic renal cell carcinoma (mRCC) J Clin Oncol 28 2010 15s:abstr 4514
26. Pantuck Gene expression and tissue microarray analysis of interleukin-2 complete responders in patients with metastatic renal cell carcinoma Proc Am Soc Clini Oncol 4 2005
27. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2009;28:2137-43.
28. Flaherty KT, Manola J, McDermott DF, et al. The BEST trial (E2804): a randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma (RCC) (abstr 345). Presented at the Genitourinary Cancers Symposium, Orlando, FL; February 14-16, 2013.
29. U.B. Dandamudi A phase II study of bevacizumab and high dose bolus aldesleukin (IL-2) in metastatic renal cell carcinoma patients: a Cytokine Working Group study J Clin Oncol 28 2010 15s:abstr 5044
30. C.A. Chambers, T.J. Sullivan, and J.P. Allison Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells Immunity 7 1997 885 895
31. G.C. Cesana, G. DeRaffele, and S. Cohen Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma J Clin Oncol 24 2006 1169 1177
32. D.I. Gabrilovich, T. Ishida, S. Nadaf, J.E. Ohm, and D.P. Carbone Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function Clin Cancer Res 5 1999 2963 2970
33. D. Gabrilovich Mechanisms and functional significance of tumour-induced dendritic-cell defects Nat Rev Immunol 4 2004 941 952
34. A.H. Zea, P.C. Rodriguez, and M.B. Atkins Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion Cancer Res 65 2005 3044 3048
35. J.S. Ko, A.H. Zea, and B.I. Rini Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients Clin Cancer Res 15 2009 2148 2157
36. J.R. Brahmer, S. Topalian, and I. Wollner Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies J Clin Oncol 2008;26 20 suppl:abstr 3006
37. J.C. Yang, M. Hughes, and U. Kammula Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis J Immunother 30 2007 825 830
38. J. Morris, G. Shapiro, and A. Tan Phase I/II study of GC1008: A human anti-transforming growth factor-beta (TGFβ) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC) J Clin Oncol 2008;26: 20 suppl:abstr 9028
39. M. Sznol, F. Hodi, and K. Margolin Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA) J Clin Oncol 2008;26 20 suppl:abstr 3007
40. H. Schmidt, P. Selby, U. Mouritzen, U.H. Thelin, P.E. Kristjansen, and P. Geertsen Subcutaneous (SC) dosing of recombinant human interleukin-21 (rIL-21) is safe and has clinical activity: Results from a dose-escalation study in stage 4 melanoma (MM) or renal cell cancer (RCC) J Clin Oncol 2008;26 20 suppl:abstr 3041
41. D.J. Moore, J. Hwang, and J. McGreivy Phase I trial of escalating doses of the TLR9 agonist HYB2055 in patients with advanced solid tumors J Clin Oncol 23 2005 16S:2503
42. A. Amin, DA, and T. Logan A phase II study testing the safety and activity of AGS-003 as an immunotherpeutic in subjets with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib J Clin Oncol 28 2010 4588
43. PA. Prieto Cytotoxic T lymphocyte-associated antigen 4 blockade with ipilimumab: long-term follow-up of 179 patients with metastatic melanoma J Clin Oncol 28 2010 15s:abstr 8544
44. A.V. Maker, G.Q. Phan, and P. Attia Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study Ann Surg Oncol 12 12 2005 1005 1016
45. R.H. Thompson, M.D. Gillett, and J.C. Cheville Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target Proc Natl Acad Sci U S A 101 2004 17174 17179
46. S.L. Topalian, F.S. Hodi, and J.R. Brahmer Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
47. J.R. Brahmer, S.S. Tykodi, and L.Q. Chow Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 2012 Jun 2
48. McDermott DF, Drake CG, Sosman JA, et al. A phase I study to evaluate the safety and antimtumor activity of biweekly BMS-936558 in patients with RCC and other advanced refractory malignancies. Ann Oncol. 2012;(23 suppl 9):ix258-93
49. Ko JS, Rayman P, Ireland J, et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 2010;70:3526-36.
50. Reinhardt C, Zdrojowy R, Szczylik C, et al. Results of a randomized phase II study investigating multipeptide vaccination with IMA901 in advanced renal cell carcinoma (RCC) [4529]. Presented at the American Society of Clinical Oncology Annual Meeting, Chicago, IL; June 4-8, 2010.
51. Rini BI, Stein M, Shannon P, et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2011;117:758-767.